<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01757691</url>
  </required_header>
  <id_info>
    <org_study_id>CFTY720D2402</org_study_id>
    <secondary_id>2012-002968-27</secondary_id>
    <nct_id>NCT01757691</nct_id>
  </id_info>
  <brief_title>Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)</brief_title>
  <official_title>A 48-week, Double-blind, Randomized, Multi-center, Parallel-group Study Comparing Structural Changes in the Retina and Evolution of Visual Function After Immediate Versus Delayed Treatment With Fingolimod in Patients With Acute Demyelinating Optic Neuritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of fingolimod 0.5mg versus placebo in patients with
      suspected acute demyelinating optic neuritis (ADON) receiving standard steroid treatment
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Discontinuation of this study was based on Novartis decision to discontinue development of
    fingolimod for the treatment of ADON
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Retinal Nerve Fiber Layer (RNFL) Thinning in Patients Treated With Fingolimod 0.5mg/Day, Relative to Patients Treated With Placebo</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>Due to early termination and low patient enrollment the primary outcome measure was not analyzed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low Contrast Visual Acuity (LCVA)</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Due to early termination and low patient enrollment this trial was not powered for efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision Based Quality of Life (QoL) Utility Score</measure>
    <time_frame>Baseline, Week 18, Week 48</time_frame>
    <description>Due to early termination and low patient enrollment this trial was not powered for efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Paatients Converting to Either 2005 or 2010 McDonald MS or to CDMS</measure>
    <time_frame>Baseline, Week 18, Week 48</time_frame>
    <description>Due to early termination and low patient enrollment this trial was not powered for efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Particpants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Weeks 0, 4, 8, 12, 18, 24, 36, 48, 60</time_frame>
    <description>Number of particpants with Adverse events as a measure of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Acute Demylelinating Optic Neuritis</condition>
  <arm_group>
    <arm_group_label>Fingolimod 0.5mg/daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral capsule dose was given once daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fingolimod 0.5mg/daily</intervention_name>
    <arm_group_label>Fingolimod 0.5mg/daily</arm_group_label>
    <other_name>FTY, Gilenya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical signs and symptoms of ADON in one eye (loss of vision, pain on movement,
             impairment of color vision)

          -  First episode of ADON

          -  Able to undergo treatment with IV steroids

        Exclusion Criteria:

          -  History of any unexplained eye or neurological symptoms lasting longer than 48 hours

          -  Optic neuritis in both eyes

          -  Concomitant condition in either eye, other than optic neuritis

          -  History of heart condition/disease

          -  Patients with uncontrolled diabetes mellitus

          -  Patients with liver conditions/disease

          -  Inability to undergo MRI

          -  Pregnant or nursing women

          -  Women of childbearing potential who are not using highly effective method of birth
             control

               -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2012</study_first_submitted>
  <study_first_submitted_qc>December 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2012</study_first_posted>
  <results_first_submitted>April 16, 2015</results_first_submitted>
  <results_first_submitted_qc>April 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2015</results_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute demyelinating optic neuritis</keyword>
  <keyword>Optic neuritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fingolimod 0.5mg/Daily</title>
          <description>Oral capsule dose was given once daily for 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fingolimod 0.5mg/Daily</title>
          <description>Oral capsule dose was given once daily for 48 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Retinal Nerve Fiber Layer (RNFL) Thinning in Patients Treated With Fingolimod 0.5mg/Day, Relative to Patients Treated With Placebo</title>
        <description>Due to early termination and low patient enrollment the primary outcome measure was not analyzed</description>
        <time_frame>Baseline and Week 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 0.5mg/Daily</title>
            <description>Oral capsule dose was given once daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Retinal Nerve Fiber Layer (RNFL) Thinning in Patients Treated With Fingolimod 0.5mg/Day, Relative to Patients Treated With Placebo</title>
          <description>Due to early termination and low patient enrollment the primary outcome measure was not analyzed</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Contrast Visual Acuity (LCVA)</title>
        <description>Due to early termination and low patient enrollment this trial was not powered for efficacy</description>
        <time_frame>Baseline, Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 0.5mg/Daily</title>
            <description>Oral capsule dose was given once daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48</description>
          </group>
        </group_list>
        <measure>
          <title>Low Contrast Visual Acuity (LCVA)</title>
          <description>Due to early termination and low patient enrollment this trial was not powered for efficacy</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vision Based Quality of Life (QoL) Utility Score</title>
        <description>Due to early termination and low patient enrollment this trial was not powered for efficacy</description>
        <time_frame>Baseline, Week 18, Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 0.5mg/Daily</title>
            <description>Oral capsule dose was given once daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48</description>
          </group>
        </group_list>
        <measure>
          <title>Vision Based Quality of Life (QoL) Utility Score</title>
          <description>Due to early termination and low patient enrollment this trial was not powered for efficacy</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Paatients Converting to Either 2005 or 2010 McDonald MS or to CDMS</title>
        <description>Due to early termination and low patient enrollment this trial was not powered for efficacy</description>
        <time_frame>Baseline, Week 18, Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 0.5mg/Daily</title>
            <description>Oral capsule dose was given once daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Paatients Converting to Either 2005 or 2010 McDonald MS or to CDMS</title>
          <description>Due to early termination and low patient enrollment this trial was not powered for efficacy</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Particpants With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>Number of particpants with Adverse events as a measure of safety and tolerability</description>
        <time_frame>Weeks 0, 4, 8, 12, 18, 24, 36, 48, 60</time_frame>
        <population>Safety population consited of all patients who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Fingolimod 0.5mg/Daily</title>
            <description>Oral capsule dose was given once daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Particpants With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>Number of particpants with Adverse events as a measure of safety and tolerability</description>
          <population>Safety population consited of all patients who received at least one dose of study medication</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non -Fatal Seriuos Aderse Event (SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety population consited of all patients who received at least one dose of study medication</desc>
      <group_list>
        <group group_id="E1">
          <title>Fingolimod 0.5mg/Daily</title>
          <description>Oral capsule dose was given once daily for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA EXACERBATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis doesn not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (i.e. data from all sites) in the clinical trial or disclosure of the trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

